ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 022,41
-0,01%
Dow Jones
37 954,11
0,47%
DAX
17 737,36
-0,64%
Brent Oil
86,855
0,51%
Bitcoin
64 495,58
1,55%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) Actualités

LXRX Lexicon Pharmaceuticals Inc

1,66
0,03 (1,84%)
Dernière mise à jour : 17:38:49
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Lexicon Pharmaceuticals Inc LXRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,03 1,84% 1,66 17:38:49
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,63 1,60 1,68 1,63
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/4/202414:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03/4/202414:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
25/3/202414:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12/3/202413:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
11/3/202421:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11/3/202412:26EDGAR2Form 8-K - Current report
11/3/202412:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11/3/202412:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11/3/202412:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
29/2/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
29/12/202323:29EDGAR2Form 8-K - Current report
29/12/202323:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/12/202322:04EDGAR2Form 8-K - Current report
21/12/202322:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30/11/202313:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22/11/202313:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
17/11/202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202323:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202320:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
10/11/202322:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
08/11/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:22EDGAR2Form 8-K - Current report
08/11/202313:00GLOBELexicon Pharmaceuticals Reports Third Quarter 2023 Financial..
03/11/202314:00GLOBELexicon Pharmaceuticals to Host Third Quarter 2023 Financial..
02/11/202314:00GLOBEData on Early Clinical Benefit for INPEFA® (Sotagliflozin)..
01/11/202314:00GLOBEINPEFA® (Sotagliflozin) Receives Coverage From Express..
31/10/202321:01GLOBELexicon Strengthens Management Team With Two New Executives
30/10/202321:01GLOBENew Data Relating to Sotagliflozin to be Presented at the..
17/10/202322:01GLOBEData From Two Studies Demonstrating Positive Financial..
11/10/202322:06EDGAR2Form 8-K - Current report
11/10/202322:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202322:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/10/202315:00GLOBEData Demonstrating Financial Impact of INPEFA®..
09/10/202322:01GLOBEINPEFA® (Sotagliflozin) Receives Preferred Formulary Status..
09/10/202314:00GLOBETom Garner Joins Lexicon as Senior Vice President and Chief..
28/9/202315:00GLOBELexicon to Present Post Hoc Analysis of Scored Clinical..
26/9/202315:00GLOBELexicon to Present Study Results Relating to Sotagliflozin..
14/9/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202322:30GLOBELexicon Pharmaceuticals to Participate in the H.C...

Dernières Valeurs Consultées

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés